Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Emmaus Life Sciences Inc. (EMMA)

0.9   0 (0%) 10-23 22:52
Open: 0.88 Pre. Close: 0.9
High: 0.9 Low: 0.88
Volume: 416 Market Cap: 44M
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 6 full-time employees. The firm is engaged in the discovery, development, marketing and sale of treatments and therapies for rare and orphan disease categories. The firm provides ENDARI, which is an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.901 - 0.906 0.906 - 0.911
Low: 0.868 - 0.874 0.874 - 0.879
Close: 0.892 - 0.901 0.901 - 0.909

Technical analysis

as of: 2020-10-23 4:43:10 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.19     One year: 1.42
Support: Support1: 0.70    Support2: 0.58
Resistance: Resistance1: 1.02    Resistance2: 1.22
Pivot: 0.89
Moving Average: MA(5): 0.88     MA(20): 0.91
MA(100): 1.47     MA(250): 1.66
MACD: MACD(12,26): -0.09     Signal(9): -0.11
Stochastic oscillator: %K(14,3): 58.33     %D(3): 52.27
RSI: RSI(14): 42.66
52-week: High: 3.25  Low: 0.70  Change(%): -60.9
Average Vol(K): 3-Month: 1919  10-Days: 3893

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
EMMA has closed below upper band by 45.3%. Bollinger Bands are 39.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 14 Oct 2020
Emmaus Life Sciences Announces the Sale of its Telcon RF Pharmaceutical Inc. Shares - BioSpace

Tue, 01 Sep 2020
Emmaus Life Sciences Announces Informational Stockholders Meeting Other OTC:EMMA - GlobeNewswire

Tue, 18 Aug 2020
Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority - GlobeNewswire

Wed, 05 Aug 2020
Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial - GlobeNewswire

Wed, 29 Jul 2020
Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari™ - GlobeNewswire

Thu, 16 Jul 2020
Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for Diverticulosis - GlobeNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Outperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 48
Shares Float (M) 29
% Held by Insiders 21.59
% Held by Institutions 0.48
Shares Short (K) 41
Shares Short P. Month (K) 34

Stock Financials

EPS -2.089
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) -0.370
Profit Margin
Operating Margin -15.20
Return on Assets (ttm) -3.2
Return on Equity (ttm)
Qtrly Rev. Growth 24.6
Gross Profit (p.s.) 0.295
Sales Per Share 0.497
EBITDA (p.s.) -0.074
Qtrly Earnings Growth
Operating Cash Flow (M) -6
Levered Free Cash Flow (M) 10

Stock Valuations

PE Ratio -0.43
PEG Ratio
Price to Book value -2.43
Price to Sales 1.81
Price to Cash Flow -7.28

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.